护理学报 ›› 2023, Vol. 30 ›› Issue (19): 41-44.doi: 10.16460/j.issn1008-9969.2023.19.041
胃癌患者报告结局评估工具的研究进展
张馥丽a, 王丹妮a, 叶红a, 蔡姣芝b
- 广东省中医院 a.肿瘤科; b.护理部,广东 广州 510120
摘要： 目的 对目前国内外胃癌患者报告结局评估工具进行综述,以期为胃癌患者报告结局评估工具的构建和应用提供依据。方法 检索国内外相关文献,对胃癌患者报告结局工具进行文献检索、整理和分析。结果 汇总了5种特异性量表和部分普适性评估工具,对各种测评工具的主要内容、应用领域、特点、优势以及局限性进行分析和总结。结论 未来的研究可对已研制成功的本土化量表进行再考评、多中心验证、推广应用;同时探索如何将患者报告结局融入临床实践,推进患者报告结局在临床实践中的常规应用。
中图分类号:
- R473.57
| [1] Baratell C, Turco CGC, Lacidogna G, et al.The role of patient-reported outcomes in outpatients receiving active anti-cancer treatment: impact on patients'quality of life[J]. Supportive Care in Cancer,2019,27(12):4697-4704.DOI:10.1007/s00520-019-04777-2. [2] 国家药监局药审中心.关于发布《患者报告结局在药物临床研发中应用的指导原则(试行)》的通告(2021年第62号)[EB/OL].[2023-07-22].https://www.cde.org.cn/main/news/viewInfoCommon/c2f79c22e8678241b030c71523eb300c. [3] Di maio M, Gallo C, Leighl NB, et al. Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized Trials[J].J Clin Oncol,2015,33(8):910-915.DOI:10.1200/JCO.2014.57.9334. [4] 张鲁敏,顾芬,任皎皎,等.护理领域患者报告结局的研究热点分析[J].医院管理论坛, 2021,38(5): 50-55.DOI:10.3969/j.issn.1671-9069.2021.05.014. [5] 杨智慧, 缪景霞, 廖荣荣,等.肿瘤免疫治疗护理相关研究的关键词可视化分析[J]. 护理学报, 2023,30(1):12-16.DOI:10.16460/j.issn1008-9969.2023.01.012. [6] Woo A, Fu T, Popovic M, et al.Comparison of the EORTC STO-22 and the FACT-Ga quality of life questionnaires for patients with gastric cancer[J]. Ann Palliat Med, 2016,5(1): 13-21.DOI: 10.3978/j.issn.2224-5820.2016.01.02. [7] Blazeby JM, Conroy T, Bottomley A, et al.Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer[J]. Eur JCancer, 2004,40(15):2260-2268.DOI:10.1016/j.ejca.2004.05.023. [8] 刘伟琳, 杨舸, 芮煜华, 等. EORTC QLQ-STO22量表对我国胃癌患者有效性的验证[J]. 肿瘤研究与临床, 2016,28(9):595-599.DOI:10.3760/cma.j.issn.1006-9801.2016.09.005. [9] Hu Y, Vos EL, Baser RE, et al.Longitudinal analysis of Quality-of-Life recovery after gastrectomy for cancer[J]. Ann Surg Oncol,2021,28(1):48-56.DOI:10.1245/s10434-020-09274-z. [10] Garland SN, Pelletier G, Lawe A, et al.Prospective evaluation of the reliability, validity, and minimally important difference of the functional assessment of cancer therapy-gastric (FACT-Ga) quality-of-life instrument[J]. Cancer, 2011,117(6):1302-1312.DOI:10.1002/cncr.25556. [11] Debb SM, Arnold B, Perez B,et al.Validation of the FACT-Gastric cancer quality of life questionnaire for use in Spanish-speaking countries[J]. Psycho-Oncology, 2011,20(1): 19-27.DOI:10.1002/pon.1698. [12] Maeda H, Sato M, Kobayashi M, et al.Validity of the Japanese version of functional assessment of cancer therapy-gastric (FACT-Ga) and its sensitivity to ascites volume change: a retrospective analysis of Japanese clinical trial participants[J]. Supportive Care in Cancer, 2016,24(11): 4515-4521.DOI:10.1007/s00520-016-3290-3. [13] Schutter K, Schulz C, Middelberg-Bisping K. Impact of gastric cancer treatment on quality of life of patients[J]. Best Pract Res Clin Gastroenterol,2021,50-51:101727.DOI:10.1016/j.bpg.2021.101727. [14] Zhu Y, Wu X, Wang W, et al.Acupuncture for quality of life in gastric cancer patients undergoing adjuvant chemotherapy[J]. J Pain Symptom Manage, 2022,63(2):210-220.DOI:10.1016/j.jpainsymman.2021.09.009. [15] Zhou HJ, So JB, Yong WP, et al.Validation of the functional assessment of cancer therapy-gastric module for the Chinese population[J]. Health Qual Life Outcomes, 2012,10: 145.DOI:10.1186/1477-7525-10-145. [16] 孟祥敏,王倩,闫荣,等.结直肠癌患者报告结局评估工具及临床应用的研究进展[J].中华护理杂志, 2022, 57(9): 1094-1099.DOI:10.3761/j.issn.0254-1769.2022.09.010. [17] Wang XS, Williams LA, Eng C, et al.Validation and application of a module of the M. D. Anderson Symptom Inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI-GI)[J]. Cancer, 2010,116(8): 2053-2063.DOI:10.1002/cncr.24920. [18] Wang XS, Wang Y, Guo H, et al.Chinese version of the M. D. Anderson Symptom Inventory:validation and application of symptom measurement in cancer patients[J]. Cancer, 2004,101(8): 1890-1901.DOI:10.1002/cncr.20448. [19] Chen R, Yang S, Xu Z, et al.Validation and Application of the Chinese Version of the M.D. Anderson Symptom Inventory Gastrointestinal Cancer Module (MDASI-GI-C)[J]. J Pain Symptom Manage,2019,57(4):820-827.DOI:10.1016/j.jpainsymman.2019.01.007. [20] 胡月,段培蓓,侯庆梅,等.胃癌术后首次化疗患者症状群与生活质量的研究[J].解放军护理杂志, 2018,35(17): 12-16.DOI: 10.3969/j.issn.1008-9993.2018.17.003. [21] Maharaj AD, Samoborec S, Evans SM, et al.Patient-reported outcome measures (PROMs) in pancreatic cancer: a systematic review[J]. HPB, 2020,22(2): 187-203.DOI:10.1016/j.hpb.2019.09.002. [22] Li N, Lu J, Xia D, et al.Serum biomarkers predict adjuvant chemotherapy-associated symptom clusters in radical resected colorectal cancer patients[J]. J Gastrointest Oncol, 2022,13(1): 197-209.DOI:10.21037/jgo-21-904. [23] Nakada K, Ikeda M, Takahashi M, et al.Characteristics and clinical relevance of postgastrectomy syndrome assessment scale (PGSAS)-45: newly developed integrated questionnaires for assessment of living status and quality of life in postgastrectomy patients[J].Gastric Cancer,2015,18(1): 147-158.DOI:10.1007/s10120-014-0344-4. [24] Misawa K, Terashlma M, Uenosono Y, et al.Evaluation of postgastrectomy symptoms after distal gastrectomy with Billroth-I reconstruction using the Postgastrectomy Syndrome Assessment Scale-45 (PGSAS-45)[J]. Gastric Cancer, 2015,18(3): 675-681.DOI:10.1007/s10120-014-0407-6. [25] Kinami S, Nakamura N, Zhiyong J, et al.Severity of postgastrectomy syndrome and quality of life after advanced gastric cancer radical gastrectomy[J].Mol Clin Oncol, 2020,13(2): 133-140.DOI:10.3892/mco.2020.2061. [26] 袁燕,张楠,王家林.胃癌患者生命质量测定量表及测量结果应用研究进展[J].中华肿瘤防治杂志, 2021, 28(9): 708-712.DOI:10.16073/j.cnki.cjcpt.2021.09.13. [27] Hu X, Zhao F, Yu H, et al.GC-PROM: validation of a patient-reported outcomes measure for Chinese patients with gastric cancer[J]. BMC Cancer, 2020,20(1): 41.DOI:10.1186/s12885-020-6518-z. [28] Dueck AC, Mendoza TR, Mitchell SA, et al.Validity and reliability of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)[J].JAMA Oncol, 2015,1(8):1051-1059.DOI:10.1001/jamaoncol.2015.2639. [29] Yoon J, Sim SH, Kang D, et al.Reliability and validity of the Korean language version of the U.S. National Cancer Institute's Patient-Reported Outcomes Common Terminology Criteria for Adverse Events[J]. J Pain Symptom Manage,2020,59(5):1082-1088.DOI:10.1016/j.jpainsymman.2020.01.015. [30] Kawguchi T, Azuma K, Sano M, et al.The Japanese version of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE): psychometric validation and discordance between clinician and patient assessments of adverse events[J]. J Patient Rep Outcomes, 2017,2(1):2.DOI:10.1186/s41687-017-0022-5. [31] Hagelstein V, Ortland I, Wilmer A, et al.Validation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)[J]. Ann Oncol, 2016,27(12): 2294-2299.DOI:10.1093/annonc/mdw422. [32] Yang S, Chen L, Liu Y, et al.Validity and reliability of the simplified Chinese patient-reported outcomes version of the common terminology criteria for adverse events[J]. BMC Cancer,2021,21(1):860.DOI:10.1186/s12885-021-08610-0. [33] Watanabe SM, Nekolaichuk C, Beaumont C, et al.A multicenter study comparing two numerical versions of the Edmonton Symptom Assessment System in palliative care patients[J]. J Pain Symptom Manage, 2011,41(2):456-468.DOI:10.1186/s12885-021-08610-0. [34] Hui D, Bruera E.The Edmonton Symptom Assessment System 25 years later: past, present, and future developments[J]. J Pain Symptom Manage,2017,53(3):630-643.DOI:10.1016/j.jpainsymman.2016.10.370. [35] Dong Y, Chen H, Zheng Y, et al.Psychometric validation of the Edmonton Symptom Assessment System in Chinese Patients[J]. J Pain Symptom Manage, 2015,50(5):712-717.DOI:10.1016/j.jpainsymman.2015.05.018. [36] Merchant SJ, Kong W, Brundage M, et al.Symptom evolution in patients with esophageal and gastric cancer receiving palliative chemotherapy: a population-based study[J].Ann Surg Oncol,2021, 28(1):79-87.DOI:10.1245/s10434-020-09289-6. [37] Bubis LD, Dellbasiv V, Davis LE, et al.Patient-reported symptoms in metastatic gastric cancer patients in the last 6 months of life[J]. Support Care Cancer, 2021,29(1): 515-524.DOI:10.1007/s00520-020-05501-1. [38] 刘佳文,赵芬,张艳娜,等.胃癌患者报告结局量表的研制与计量心理学特征考核[J].中国卫生统计,2019,36(3):330-333. [39] 曹娟,李方,田雅丽,等.早期肺癌术后患者报告结局量表编制及信效度检验[J].护理学杂志, 2023,38(7):35-39.DOI:10.3870/j.issn.1001-4152.2023.07.03. |
| [1] | 杜易梅, 刘莉, 郭立丽, 卢吉, 付苗苗, 刘杰. 妇科恶性肿瘤患者性健康研究进展[J]. 护理学报, 2025, 32(4): 28-33. |
| [2] | 李垚, 陈小敏, 夏敏, 吴茜, 张琳, 陈叡喆, 葛莉丽, 吴逸梅. 肿瘤患者衰弱评估工具应用的范围综述[J]. 护理学报, 2025, 32(4): 48-52. |
| [3] | 陈恩琳, 莫丰菱, 庄泽明, 张明哲, 周佳坤, 黄丽芳, 纪龙飞, 张莉芳. 脑卒中单侧空间忽略评估工具的范围综述[J]. 护理学报, 2025, 32(3): 43-49. |
| [4] | 李丁丁, 王帅有, 朱杉杉, 郭鑫, 张会敏, 王宏茹, 潘勤. 脑卒中患者支持性照护需求评估工具的范围综述[J]. 护理学报, 2024, 31(9): 48-53. |
| [5] | 陈思齐, 刘宁, 侯晓敏, 卢舒颖. 机器人胃癌手术围术期加速康复外科护理的最佳证据总结[J]. 护理学报, 2024, 31(8): 31-36. |
| [6] | 莫然, 常晓未, 马芳芳, 顾晴. 18例肿瘤患者并发危重度免疫检查点抑制剂相关心肌炎的护理[J]. 护理学报, 2024, 31(8): 60-62. |
| [7] | 王薇, 周演铃, 薛文萍, 张淋淋, 林书球. 老年髋部骨折患者衰弱评估工具的范围综述[J]. 护理学报, 2024, 31(4): 42-47. |
| [8] | 李佳萍, 朱云霞, 朱宇. 乳腺癌化疗患者症状群的范围综述[J]. 护理学报, 2024, 31(4): 60-64. |
| [9] | 蔡佳佳, 施忠英, 黄楚贤. 进食障碍患者情绪调节评估工具的研究进展[J]. 护理学报, 2024, 31(3): 41-45. |
| [10] | 江艳, 唐文娟, 赵海燕, 范巧玲. 新生儿营养风险筛查工具的研究进展[J]. 护理学报, 2024, 31(22): 26-29. |
| [11] | 唐昕宇, 陈昌连, 张绍青, 曹家燕. 基于理论域框架的胃癌患者一级亲属健康行为促进与障碍因素分析[J]. 护理学报, 2024, 31(20): 73-78. |
| [12] | 张亦然, 王康美, 朱盛财, 朱璐, 黄沂. 中文版高血压患者自我管理评估工具的系统评价：基于COSMIN指南[J]. 护理学报, 2024, 31(19): 52-57. |
| [13] | 史晨, 闫泽霖, 马嘉骏, 李新旭, 欧春泉. 临床研究中基于患者报告结局的缺失值问题及对策[J]. 护理学报, 2024, 31(18): 35-38. |
| [14] | 郭世鸿, 柏晓玲, 楼婷, 余娜, 杨曾桢, 牛雨田, 李慧. 口腔衰弱评估工具的范围综述[J]. 护理学报, 2024, 31(14): 52-56. |
| [15] | 黄子菁, 王颖, 朱丽, 马婉秋, 杜玫洁, 崔梦影, 蔡悦, 张昕悦, 陈敏, 鲁志卉. 胃肠道肿瘤患者术前口服营养补充指南的质量评价及内容分析[J]. 护理学报, 2024, 31(11): 42-47. |
|
||